Volume 9, Issue 8, Pages S3-S13 (August 2012)

Slides:



Advertisements
Similar presentations
Presenter Disclosure Information John F. Beshai, MD RethinQ Trial Results Disclosures Information: The following relationships exist related to this presentation:
Advertisements

Target Study Cardiac resynchronization therapy (CRT) is an established treatment for advanced heart failure symptoms, impaired LV systolic function, and.
Cardiac Resynchronization Therapy (CRT) Is an Effective Treatment for Heart Failure and Indications Are Expanding Multiple trials have shown the clinical.
Date of download: 6/1/2016 From: Systematic Review: Cardiac Resynchronization in Patients with Symptomatic Heart Failure Ann Intern Med. 2004;141(5):
Copyright © 2011 American Medical Association. All rights reserved.
Treatment options for patients with chronic symptomatic systolic heart failure. ACE, angiotensinconvertingenzyme; ARB, angiotensin receptor blocker; CRT-D,
Comparison of Low Versus High (>40 mm Hg) Pulse Pressure to Predict the Benefit of Cardiac Resynchronization Therapy for Heart Failure (from the Multicenter.
Identifying patients for advanced heart failure therapy by screening patients with cardiac resynchronization therapy or implantable cardioverter-defibrillator:
Utility of the Seattle Heart Failure Model in patients with cardiac resynchronization therapy and implantable cardioverter defibrillator referred for.
Treatment options for patients with chronic symptomatic systolic heart failure. ACE, angiotens inconverting enzyme; ARB, angiotensin receptor blocker;
Volume 12, Issue 10, Pages (October 2015)
Volume 5, Issue 8, Pages (August 2008)
Wearable cardioverter-defibrillator for prevention of sudden cardiac death after infected implantable cardioverter-defibrillator removal: A cost-effectiveness.
CHronic use of Amiodarone aGAinSt Implantable cardioverter-defibrillator therapy for primary prevention of death in patients with Chagas cardiomyopathy.
Can the Seattle Heart Failure Model Be Used to Risk-stratify Heart Failure Patients for Potential Left Ventricular Assist Device Therapy?  Wayne C. Levy,
2) Massachusetts General Hospital, 55 Fruit St, Boston, MA 02114
Canadian Cardiovascular Society Guidelines on the Use of Cardiac Resynchronization Therapy: Implementation  Ratika Parkash, MD, MSc, François Philippon,
Volume 15, Issue 1, Pages (January 2018)
Diabetes Mellitus and Heart Failure
Canadian Cardiovascular Society Guidelines on the Use of Cardiac Resynchronization Therapy: Evidence and Patient Selection  Derek V. Exner, MD, MPH, David.
Erratum Heart Rhythm Volume 8, Issue 4, (April 2011)
Volume 5, Issue 4, Pages (April 2008)
Volume 11, Issue 9, Pages (September 2014)
Volume 12, Issue 3, Pages (March 2015)
Volume 14, Issue 9, Pages (September 2017)
Study Design Patients with LBBB and LV dysfunction
Volume 6, Issue 10, Pages (October 2009)
Volume 11, Issue 1, Pages (January 2014)
Gaurav A. Upadhyay, MD, Jonathan S. Steinberg, MD  Heart Rhythm 
Thinking beyond resynchronization therapy in the failing heart
Volume 6, Issue 12, Pages (December 2009)
Angelo Auricchio, and Frits W. Prinzen JACEP 2017;3:
Volume 13, Issue 7, Pages (July 2016)
Volume 15, Issue 3, Pages (March 2018)
Volume 7, Issue 1, Pages (January 2010)
Volume 15, Issue 9, Pages (September 2018)
Effects of tai chi mind-body movement therapy on functional status and exercise capacity in patients with chronic heart failure: A randomized controlled.
Volume 11, Issue 2, Pages (February 2014)
Volume 15, Issue 10, Pages e253-e274 (October 2018)
Volume 9, Issue 1, Pages (January 2012)
Volume 5, Issue 8, Pages (August 2008)
Volume 9, Issue 6, Pages (June 2012)
Ethnic and racial disparities in cardiac resynchronization therapy
Volume 13, Issue 8, Pages (August 2016)
Volume 14, Issue 12, Pages (December 2017)
Outcomes After Ventricular Fibrillation Out-of-Hospital Cardiac Arrest: Expanding the Chain of Survival  T. Jared Bunch, MD, Stephen C. Hammill, MD, Roger.
Shannon M. Dunlay, MD, MS, Naveen L. Pereira, MD, Sudhir S
Angelo Auricchio, and Frits W. Prinzen JACEP 2017;j.jacep
Standard cardiac resynchronization therapy with a second right ventricular lead for severe right ventricular heart failure in 2 patients with repaired.
Understanding the cardiac substrate and the underlying physiology: Implications for individualized treatment algorithm  John Gorcsan, MD, Frits W. Prinzen,
Volume 9, Issue 1, Pages (January 2012)
Volume 7, Issue 7, Pages (July 2010)
Volume 14, Issue 12, Pages (December 2017)
Volume 12, Issue 10, Pages (October 2015)
Volume 9, Issue 8, Pages S14-S17 (August 2012)
Volume 7, Issue 3, Pages (March 2010)
Michael R. Gold, MD, PhD, FHRS  Heart Rhythm 
Volume 15, Issue 1, Pages (January 2018)
Emilce Trucco et al. JACEP 2018;j.jacep
Volume 11, Issue 3, Pages (March 2014)
Appropriate use of genetics in a young patient with atrioventricular block and family history of sudden cardiac death  Johnni Rudbeck-Resdal, MD, Jens.
Volume 7, Issue 11, Pages (November 2010)
Volume 8, Issue 1, Pages (January 2011)
Volume 8, Issue 3, Pages (March 2011)
Abdominal implantable cardioverter-defibrillator placement in a patient requiring bilateral chest radiation therapy  Ankur A. Karnik, MD, FHRS, CCDS,
Volume 7, Issue 8, Pages (August 2010)
Saadia Sherazi et al. JACEP 2015;1:74-80
Cardiac Resynchronization Therapy: Long-Term Alternative to Cardiac Transplantation?  Bert Hansky, MD, Jürgen Vogt, MD, Armin Zittermann, PhD, Holger Güldner,
Resolution of new left bundle branch block and ventricular tachycardia with immunosuppressive therapy in a patient with cardiac sarcoidosis  Aatish Garg,
Volume 16, Issue 6, Pages (June 2019)
Presentation transcript:

Volume 9, Issue 8, Pages S3-S13 (August 2012) Cardiac resynchronization therapy (CRT): Clinical trials, guidelines, and target populations  Cecilia Linde, MD, PhD, Kenneth Ellenbogen, MD, FHRS, Finlay A. McAlister, MD  Heart Rhythm  Volume 9, Issue 8, Pages S3-S13 (August 2012) DOI: 10.1016/j.hrthm.2012.04.026 Copyright © 2012 Heart Rhythm Society Terms and Conditions

Figure 1 Uncertainty of link between interventricular and intraventricular dyssynchrony, and QRS morphology. %DLC = extent of myocardium showing delayed longitudinal contraction; Inter-V = interventricular dyssynchrony; SD-12 = standard deviation of TP of the 12 left ventricular segments; TO-6base = maximal difference in TO between any two of six basal left ventricular segments; TP-6base = maximal difference in TP between any two of six basal segments; TP-sep-lat = difference between TP of septobasal and laterobasal segments. Reproduced with permission from Ghio S, Constantin C, Klersy C, et al. Eur Heart J 2004. Heart Rhythm 2012 9, S3-S13DOI: (10.1016/j.hrthm.2012.04.026) Copyright © 2012 Heart Rhythm Society Terms and Conditions

Figure 2 A: As shown in several clinical trials, for patients with moderate-to-severe heart failure (HF; New York Heart Association [NYHA] class III–IV), cardiac resynchronization therapy (CRT) provides very consistent improvements in NYHA functional class ranking, exercise capacity (measured by 6-minute hall walk distance), and peak oxygen consumption. B: As shown in several clinical trials, for patients with moderate-to-severe HF (NYHA class III–IV), CRT provides very consistent improvements in NYHA functional class ranking, exercise capacity (measured by 6-minute hall walk distance), and peak oxygen consumption. Heart Rhythm 2012 9, S3-S13DOI: (10.1016/j.hrthm.2012.04.026) Copyright © 2012 Heart Rhythm Society Terms and Conditions

Figure 3 MADIT-CRT—significant reduction in relative risk of sustaining a primary endpoint with CRT-D. CRT = cardiac resynchronization therapy; HF = heart failure. Adapted from Moss et al.20 Heart Rhythm 2012 9, S3-S13DOI: (10.1016/j.hrthm.2012.04.026) Copyright © 2012 Heart Rhythm Society Terms and Conditions

Figure 4 REVERSE—time to first hospitalization for management of congestive heart failure (HF) or to death from any cause was significantly delayed. CRT = cardiac resynchronization therapy. Adapted from Linde et al.19 Heart Rhythm 2012 9, S3-S13DOI: (10.1016/j.hrthm.2012.04.026) Copyright © 2012 Heart Rhythm Society Terms and Conditions

Figure 5 RAFT—primary endpoint. CRT = cardiac resynchronization therapy; ICD = implantable cardioverter-defibrillator. Adapted from Tang et al.21 Heart Rhythm 2012 9, S3-S13DOI: (10.1016/j.hrthm.2012.04.026) Copyright © 2012 Heart Rhythm Society Terms and Conditions

Figure 6 Composite clinical score from MIRACLE-ICD II. CRT = cardiac resynchronization therapy. Adapted from Abraham et al.14 Heart Rhythm 2012 9, S3-S13DOI: (10.1016/j.hrthm.2012.04.026) Copyright © 2012 Heart Rhythm Society Terms and Conditions

Figure 7 Composite clinical score from PROSPECT. Adapted from Chung et al.33 Heart Rhythm 2012 9, S3-S13DOI: (10.1016/j.hrthm.2012.04.026) Copyright © 2012 Heart Rhythm Society Terms and Conditions